Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CERE | Common Stock | Award | +3.28K | +11.5% | 31.8K | Jun 7, 2023 | Direct | F1 | ||
holding | CERE | Common Stock | 602K | Jun 7, 2023 | See footnote | F2, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CERE | Stock Option (Right to Buy) | Award | $0 | +13.8K | $0.00 | 13.8K | Jun 7, 2023 | Common Stock | 13.8K | $32.60 | Direct | F4 |
Id | Content |
---|---|
F1 | The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. |
F2 | On June 7, 2023, BC Perception Holdings, LP ("BC Perception") distributed an aggregate of 432,627 shares of Common Stock to certain of its limited partners (including Novalis LifeSciences Investments I, L.P., "Novalis LifeSciences") in a pro-rata in-kind distribution to such limited partners in connection with a redemption of their partnership interests. Includes 402,326 shares of Common Stock received by Novalis LifeSciences in the distribution described herein made in accordance with the exemptions afforded under Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. |
F3 | Represents shares held by Novalis LifeSciences. The Reporting Person, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
F4 | 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. |